Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2045-2322

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders ; volume:8 ; number:1 ; day:5 ; month:9 ; year:2018 ; pages:1-9 ; date:12.2018
Scientific reports ; 8, Heft 1 (5.9.2018), 1-9, 12.2018

Creator: Hall, Sara

Contributor: Janelidze, Shorena
Surova, Yulia
Widner, Håkan
Zetterberg, Henrik
Hansson, Oskar
SpringerLink (Online service)

DOI: 10.1038/s41598-018-31517-z

URN: urn:nbn:de:101:1-2018102023105430362946

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:23 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Hall, Sara
Janelidze, Shorena
Surova, Yulia
Widner, Håkan
Zetterberg, Henrik
Hansson, Oskar
SpringerLink (Online service)

Other Objects (12)

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Fluid biomarkers in Alzheimer’s disease – current concepts

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Factors associated with fear of falling in people with Parkinson’s disease

The clinical significance of 10-m walk test standardizations in Parkinson’s disease

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

External validation of a 3-step falls prediction model in mild Parkinson’s disease

Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Fluid biomarkers in Alzheimer’s disease – current concepts

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Factors associated with fear of falling in people with Parkinson’s disease

The clinical significance of 10-m walk test standardizations in Parkinson’s disease

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

External validation of a 3-step falls prediction model in mild Parkinson’s disease

Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Fluid biomarkers in Alzheimer’s disease – current concepts

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Factors associated with fear of falling in people with Parkinson’s disease

The clinical significance of 10-m walk test standardizations in Parkinson’s disease

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

External validation of a 3-step falls prediction model in mild Parkinson’s disease

Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Fluid biomarkers in Alzheimer’s disease – current concepts

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Factors associated with fear of falling in people with Parkinson’s disease

The clinical significance of 10-m walk test standardizations in Parkinson’s disease

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

External validation of a 3-step falls prediction model in mild Parkinson’s disease

Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Fluid biomarkers in Alzheimer’s disease – current concepts

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Factors associated with fear of falling in people with Parkinson’s disease

The clinical significance of 10-m walk test standardizations in Parkinson’s disease

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

External validation of a 3-step falls prediction model in mild Parkinson’s disease

Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Fluid biomarkers in Alzheimer’s disease – current concepts

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Factors associated with fear of falling in people with Parkinson’s disease

The clinical significance of 10-m walk test standardizations in Parkinson’s disease

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

External validation of a 3-step falls prediction model in mild Parkinson’s disease

Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions

Related objects

Reset password